Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03223844
Other study ID # 16969
Secondary ID
Status Recruiting
Phase N/A
First received July 8, 2017
Last updated April 18, 2018
Start date January 1, 2018
Est. completion date December 2021

Study information

Verified date April 2018
Source Medical University of Vienna
Contact Ana Weidenauer, MD
Phone +43140400
Email ana.weidenauer@meduniwien.ac.at
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with schizophrenia show enhanced dopamine synthesis capacity and release, an effect that can be evoked in healthy subjects by repeated amphetamine administration. Therefore for the first time the relationship between dopamine synthesis and release will be studied in healthy subjects before and after amphetamine sensitization in order to better understand adaptive mechanisms of the dopamine system.


Description:

Positron emission tomography (PET) studies have consistently shown increased brain dopamine (DA) synthesis and enhanced d-amphetamine-induced DA release in patients with schizophrenia. Repeated administration of d-amphetamine leads to an increased subjective and behavioral drug-response. This effect, termed "sensitization", is paralleled by an increase in dopamine release to levels akin to those observed in schizophrenia. Schizophrenia thus goes along with a state of 'natural sensitization' towards amphetamines. However, while it is known that DA synthesis and release are both enhanced in schizophrenia, it is unknown whether sensitization changes indices of presynaptic DA synthesis in the striatum of healthy subjects. Thus, for the first time, this project will study the effects of repeated d-amphetamine on uptake of the DA precursor [18F]FDOPA and on d-amphetamine-induced changes in binding of the D2/3 receptor agonist radioligand [11C]-(+)PHNO in a within-subject design. Before and after amphetamine sensitization by repeated intermittent administration subjects will receive an [18F]FDOPA and and a [11C]-(+)PHNO PET scan. For the investigation of the influence of functional and structural cortical properties on dopamine synthesis and release, functional and structural magnet resonance imaging will be performed before and after sensitization.


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date December 2021
Est. primary completion date August 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Males and females aged 18-65, in good general health based on history and physical examination

- Psychiatrically healthy as determined by the Mini-International Neuropsychiatric Interview (M.I.N.I.PLUS) (94))

- No relevant abnormalities in laboratory screening including thyroid function tests, blood cell count, serum electrolytes, liver and kidney function, and urinalysis

- No clinically relevant findings in electrocardiography (ECG)

- No clinically relevant findings in vital signs (blood pressure and pulse)

- No regular use of illegal drugs or alcohol abuse based on declared history and confirmed by urine drug screening

- No history of repeated AMPH (AMPH), cocaine or other stimulant drug use

Exclusion Criteria:

- Evidence of present psychiatric or neurological illness according to M.I.N.I.-Plus (any personal or first-degree relative history of: schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and substance dependence)

- Recreational use of psychostimulant drugs in the past two years; lifetime use of psychostimulants exceeding five exposures

- Medically significant biochemical or hematological abnormality on screening laboratory studies

- Women of childbearing potential: Current pregnancy or breast-feeding

- Clinically relevant abnormalities in the electro-cardiogram (ECG)

- History of myocardial infarction or angina pectoris

- Positive urine drug screen within one week prior to PET study day

- Presence of ferromagnetic metal in the body or heart pacemaker

- Claustrophobia

- Any history of arterial hypertension or paroxysmal hypertensive states

- Established diagnosis of advanced arteriosclerosis

- Established diagnosis of hyperthyroidism

- History of hypersensitivity to sympathomimetics

- History of head trauma resulting in loss of consciousness that required medical intervention

- Lifetime history of substance dependence (except nicotine)

- If participation in this study would exceed the annual radiation dose limits (30 mSv) for human subjects

- Subjects currently participating in research studies

- Suicidal ideation or likelihood of a suicide or homicide attempt

Study Design


Intervention

Drug:
Dextroamphetamine Sulfate
Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.

Locations

Country Name City State
Austria Medical University of Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

References & Publications (2)

Sauerzopf U, Sacco R, Novarino G, Niello M, Weidenauer A, Praschak-Rieder N, Sitte H, Willeit M. Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. Eur J Neurosci. 2017 Jan;45(1):45-57. doi: 10.1111/ejn.13418. Epub 2016 Oct 19. Review. — View Citation

Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Praschak-Rieder N, Sitte HH, Kasper S, Willeit M. Making Sense of: Sensitization in Schizophrenia. Int J Neuropsychopharmacol. 2016 Dec 31;20(1):1-10. doi: 10.1093/ijnp/pyw081. Print 2017 Jan. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary [18F]FDOPA Ki values Relative change in regional [18F]FDOPA Ki values after AMPH sensitization Baseline and 2 weeks after amphetamine sensitization, Week 1 and Week 4
Secondary [11C]-(+)-PHNO BPND values Relative change in regional [11C]-(+)-PHNO BPND values after AMPH administration before and after sensitization Baseline and 2 weeks after amphetamine sensitization, Week 1 and Week 4
Secondary Subjective ratings of amphetamine effects (Drug Effects Questionnaire) Subjective ratings will be assessed via questionnaire (Drug Effects Questionnaire) four times throughout the study. Baseline, after i.v. amphetamine during PHNO PET, on each of the two sensitization visits and 2 weeks after amphetamine sensitization during PHNO PET scanning over the course of 4 weeks. Time points: Week 1 Week 2 Week 4
Secondary Subjective ratings of amphetamine effects (Subjective States Questionnaire) Subjective ratings will be assessed via questionnaire (Subjective States Questionnaire) four times throughout the study. Baseline, after i.v. amphetamine during PHNO PET, on each of the two sensitization visits and 2 weeks after amphetamine sensitization during PHNO PET scanning over the course of 4 weeks. Time points: Week 1 Week 2 Week 4
Secondary Cognitive measures Working memory, reward processing and impulsivity will be assessed via a computerized test battery four times throughout the study At baseline, on each of the two sensitization visits after amphetamine administration and 2 weeks after amphetamine sensitization before FDOPA scanning, total timeframe 4 weeks, Time points: Week 1 Week 2 Week 4
Secondary Impulsiveness The personality traits impulsiveness will be assessed once during study participation by the questionnaire Barrat Impulsiveness Scale (BIS). Baseline, Week 1
Secondary Personality-related markers Personality traits like novelty seeking will be assessed once during study participation using the Temperament and Character Inventory (TCI). Baseline, Week 1
Secondary Peripheral markers of sensitization Plasma concentration of the dopamine metabolite HVA, glucose and insulin metabolism related parameters (glucose, glucagon, insulin, c-peptide, somatostatin), plasma cocaine and AMPH-regulated transcript (CART) levels will be measured at each PET study day. Baseline FDOPA scan, baseline PHNO + amphetamine scan, post-sensitization PHNO+ amphetamine scan, post-sensitization FDOPA scan, Time points: Week 1 Week 2 Week 4
Secondary Salivary cortisol Salivary cortisol will be assessed using Salivettes ®. Salivary cortisol will be assessed each time amphetamine is administered: At baseline and 30, 60, 90, 145 and 210 minutes after i.v. or oral amphetamine administration.
Secondary Fractional anisotropy (diffusion-weighted tensor imaging) of white matter Fractional anisotropy of white matter will be measured by means of magnet resonance imaging. Before and after amphetamine sensitization, Week 1, Week 5
Secondary Gray matter volume Gray matter volume will be measured by means of magnet resonance imaging. T1 and PD sequences will be recorded. Before and after amphetamine sensitization, Week 1, Week 5
Secondary Functional connectivity Functional connectivity between brain regions will be measured by means of magnet resonance imaging during a resting state of the subject. Before and after amphetamine sensitization, Week 1, Week 5
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A